Potential use of (1,3)-beta-D-glucan as target of diagnosis and treatment of keratomycosis.
Kaji
Yuichi
Y
Department of Ophthalmology, University of Tsukuba Institute of Clinical Medicine, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8565, Japan. sanken-tky@umin.ac.jp
Hiraoka
Takahiro
T
Oshika
Tetsuro
T
D000818:Animals; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology*; D003316:Corneal Diseases / Q000188:drug therapy / Q000382:microbiology*; D054714:Echinocandins; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000382:microbiology*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D008033:Limulus Test; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use*; D008297:Male; D000077551:Micafungin; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011817:Rabbits; D013666:Tears / Q000382:microbiology*; D047071:beta-Glucans
D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D047071:beta-Glucans; C033363:beta-1,3-glucan; D005964:Glucosyltransferases; C020570:1,3-beta-glucan synthase; D000077551:Micafungin